Aase and Ejnar Danielsens Foundation   Report issue

Foundation Phase 3 Phase 4
Founded: Lyngby Denmark (1975)

Organization Overview

First Clinical Trial
2006
NCT00328796
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

Aase and Ejnar Danielsens Foundation

Active Ingredients

Drugs in Phase 4 Trials (1)

cefuroxime (zinacef) (1 trial)

Drugs in Phase 3 Trials (4)

alteplase (Activase) (1 trial)

fibrinogen (human) (RiaSTAP) (1 trial)

melatonin (1 trial)

sodium chloride (1 trial)

Drugs in Other Trials (1)

lidocaine (xylocaine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 4)

Fatigue (Phase 3)

Hemorrhage (Phase 3)

Infections (Phase 4)

Postpartum Hemorrhage (Phase 3)

Stroke (Phase 3)

Surgical Wound (Phase 4)

Surgical Wound Infection (Phase 4)

Wound Infection (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 6